Detail akcie Centessa Sp ADS online

Business Summary: Centessa Pharmaceuticals plc is a United Kingdom-based clinical-stage pharmaceutical company. Its advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on its LockBody technology platform. SerpinPC, its advanced product candidate, is an investigational, potentially first-in-class subcutaneously administered novel inhibitor of activated protein C for hemophilia. Its Orexin Receptor 2 (OX2R) Agonist Program includes ORX750, which is an investigational, orally administered, selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 and to address sleep-wake disorders with normal orexin levels such as narcolepsy type 2 and idiopathic hypersomnia. It is also exploring follow-up orexin agonists for potential expansion opportunities into a range of sleep-wake disorders and broader neurological indications.
Financial Summary: BRIEF: For the nine months ended 30 September 2024, Centessa Pharmaceuticals PLC - ADR revenues was not reported. Net loss increased 9% to $124.4M. Higher net loss reflects Stock-based Compensation in SGA increase of 14% to $13.8M (expense), Stock-based Compensation in R&D increase of 15% to $11.4M (expense), Labor & Related Expenses in R&D increase of 4% to $26.3M (expense).